Genuity Capital Markets
http://www.genuitycm.com/Genuity Capital Markets is a financial services firm providing investment banking, institutional sales and trading, and equity research to its corporate clients. The firm uses a simple Buy, Hold and Sell rating system in its research analysis.
-
Canaccord Genuity Remains Buyers of Heartware Intl (HTWR) at Current Levels
-
Canaccord Genuity Reaffirms a 'Buy' on Heartware Intl (HTWR); Management Meeting Takeaways Reaffirm Thesis
-
Canaccord Genuity Reiterates a 'Buy' on Heartware Intl (HTWR); Q1 as Expected
-
Canaccord Genuity Maintains a 'Hold' on Thoratec (THOR); Sequential US VAD Trends Bode Well for VAD Bulls
-
Canaccord Genuity Reiterates a 'Buy' on Heartware Intl (HTWR); Q1 Preview; Also Buyers of THOR
-
Canaccord Genuity Reiterates a 'Buy' on Heartware (HTWR); Solid HVAD Data at ISHLT
-
Canaccord Genuity Reiterates a 'Buy' on Heartware Intl (HTWR)
-
Canaccord Genuity Reiterates a 'Buy' on Heartware Intl (HTWR); Strong Q4; Gearing Up for US Launch and Continued EU Ramp
-
Canaccord Genuity Maintains a 'Hold' on Thoratec (THOR); Share Repurchase Gives Us Mixed Feelings
-
Canaccord Genuity Downgrades Thoratec (THOR) to Hold on Weak 2011 Guidance
-
Canaccord Genuity Reiterates a 'Buy' on Heartware Intl (HTWR); Changes Coming to LVAD Market
-
Canaccord Genuity Reiterates a 'Buy' on Heartware Int'l; Q4 Revenue Above Expectations; Reaffirms Bullish View on HTWR & THOR
-
Canaccord Genuity Reiterates a 'Buy/Best Idea' on Heartware (HTWR); Capital Raise Puts HTWR in Position to Commercialize HVAD in US
-
Canaccord Genuity Morning Coffee on HeartWare (HTWR) and Thoratec (THOR): Starts Off With a Vang
-
Notable Analyst Rating Changes 11/15: SNV, HTWR, CL, JCG Upgraded; LLNW, THOR, AKAM, RAX Downgraded
-
Canaccord Genuity on Life Sciences -- Biomedical Devices and Services: Stellar HVAD BTT Data at AHA - Implications for HTWR and THOR
-
Canaccord Genuity AHA Preview: Focus on LVADS - Would be Buyers of HTWR & THOR Heading Into AHA
-
Canaccord Genuity Maintains a 'Buy' on HeartWare Int'l (HTWR); FDA Approves Second CAP
